Amh Equity LTD Harvard Bioscience Inc Transaction History

Amh Equity LTD

$71.7 Million
Q2 2024

A detailed history of Amh Equity LTD transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Amh Equity LTD holds 2,199,922 shares of HBIO stock, worth $5.17 Million. This represents 8.75% of its overall portfolio holdings.

Number of Shares

2,199,922

Previous 2,324,200 5.35%

Holding current value

$5.17 Million

Previous $9.85 Million 36.38%

% of portfolio

8.75%

Previous 10.16%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$2.77 - $4.63 $344,250 - $575,407	-124,278 Reduced 5.35%	2,199,922 $6.27 Million
Q1 2024 May 06, 2024	BUY	$4.02 - $5.39 $648,454 - $869,444	161,307 Added 7.46%	2,324,200 $9.85 Million
Q4 2023 Feb 02, 2024	BUY	$4.0 - $5.49 $86,160 - $118,254	21,540 Added 1.01%	2,162,893 $11.6 Million
Q3 2023 Nov 06, 2023	BUY	$4.0 - $5.82 $565,412 - $822,674	141,353 Added 7.07%	2,141,353 $9.21 Million
Q2 2023 Aug 01, 2023	SELL	$4.19 - $6.16 $225,870 - $332,067	-53,907 Reduced 2.62%	2,000,000 $11 Million
Q1 2023 May 02, 2023	SELL	$2.45 - $4.22 $490,000 - $844,000	-200,000 Reduced 8.87%	2,053,907 $8.63 Million
Q4 2022 Jan 20, 2023	BUY	$2.12 - $2.86 $1.34 Million - $1.81 Million	633,124 Added 39.06%	2,253,907 $0
Q3 2022 Nov 03, 2022	BUY	$2.33 - $3.92 $863,924 - $1.45 Million	370,783 Added 29.66%	1,620,783 $4.15 Million
Q2 2022 Aug 01, 2022	BUY	$3.28 - $6.42 $1.55 Million - $3.04 Million	473,747 Added 61.03%	1,250,000 $0
Q1 2022 Apr 26, 2022	SELL	$5.16 - $7.14 $122,534 - $169,553	-23,747 Reduced 2.97%	776,253 $4.82 Million
Q4 2021 Jan 24, 2022	BUY	$6.37 - $8.18 $5.1 Million - $6.54 Million	800,000 New	800,000 $5.64 Million

Others Institutions Holding HBIO

# of Institutions

105

Shares Held

32M

Call Options Held

1.2K

Put Options Held

1.2K

View Full List

About HARVARD BIOSCIENCE INC

Ticker HBIO
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 41,636,500
Market Cap $97.8M
Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...

More about HBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Amh Equity LTD, based on Form 13F filings with the SEC.

News

Stay updated on Amh Equity LTD with notifications on news.

Account